Products with Antileukaemic bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN5371 | Pseudolycorine |
| 1. Pseudolycorine can halt HeLa cell growth at 10-1 mM or lower concentrations, it at its growth inhibitory concentrations blocks protein synthesis in ascites cells and stabilize HeLa cell polysomes in vivo. 2. Pseudolycorine exhibits cytotoxic profiles against cancer cell lines. 3. Pseudolycorine and haemanthamine show good activity in in vitro assays against Trypanosoma brucei rhodesiense, T. cruzi and Plasmodium falciparum with IC50 values in the range of 3.66 uM or lower. 4. Pseudolycorine, primarily studied as a new antiviral agent , it also shows remarkable antileukemic activity. | |
| BCN5389 | Cordycepin |
| Cordycepin possesses immunological stimulating,anti-hyperglycemia, anti-cancer, neuroprotective, antifungal, antibacterial, anti-inflammatory, anti-virus and anti-infection activities. Cordycepin has inhibitory effects on osteoclast differentiation in vitro and that it suppresses inflammatory bone loss in vivo. Cordycepin inhibited the production of NO production by down-regulation of iNOS and COX-2 gene expression via the suppression of NF-κB activation, Akt and p38 phosphorylation, suppressed HMGA2, Twist1 and ZEB1-dependent melanoma invasion and metastasis by targeting miR-33b. | |
| BCN5393 | Cepharanthine |
| Cepharanthine has anti-plasmodial, anti-tumor , anti-inflammatory, antiallergic, antioxidant, and immunomodulatory activities in vivo, and it is a highly potent inhibitor of HIV-1 replication in a chronically infected monocytic cell line. Cepharanthine inhibits the HIV-1 entry process by reducing plasma membrane fluidity, and the plasma membrane is therefore an identical target to prevent viral infection. | |
| BCN5402 | Bakkenolide A |
| 1. Bakkenolide A has antifeedant and growth inhibitory effects on neonate variegated cutworms. 2. Bakkenolide A inhibits leukemia by regulation of HDAC3 and PI3K/Akt-related signaling pathways. | |
| BCN5411 | Vincristine |
| Vincristine-induced nociceptive painful sensation, may be due to its potential of antioxidative, neuroprotective and calcium channel inhibitory action.Vincristine can treat MM, ERK1/2, Akt, and NF-κB inhibitors are potentially useful as anti-MDR agents for the treatment of Vincristine-resistant MM. An inherited polymorphism in the promoter region of CEP72 was associated with increased risk and severity of Vincristine-related peripheral neuropathy. | |
